AP report. Notably, Pfizer plans to submit the findings to U.S. regulators later this week. The Food and Drug Administration already is evaluating an application by rival Moderna to offer two-dose vaccinations to children and set June 15 as a tentative date for its independent scientific advisers to publicly debate the data from one or both companies.
The development comes after months of anxious waiting by parents desperate to vaccinate their babies, toddlers and preschoolers, especially as Covid-19 cases once again are rising.
The 18 million youngsters under 5 are the only group in the U.S. not yet eligible for Covid-19 vaccination. Pfizer has had a bumpy time figuring out its approach.
It aims to give children an extra low dose, just one-tenth of the amount adults receive but discovered during its trial that two shots didn't seem quite strong enough for preschoolers.